Victory Capital Management Inc. Buys New Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

Victory Capital Management Inc. bought a new stake in Astrana Health, Inc. (NASDAQ:ASTH) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 44,806 shares of the company’s stock, valued at approximately $2,596,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in Astrana Health in the third quarter valued at $34,000. Nisa Investment Advisors LLC acquired a new position in Astrana Health in the third quarter valued at $35,000. Central Pacific Bank Trust Division acquired a new position in Astrana Health in the third quarter valued at $160,000. Everence Capital Management Inc. acquired a new position in Astrana Health in the third quarter valued at $272,000. Finally, Granite Bay Wealth Management LLC acquired a new position in Astrana Health in the third quarter valued at $290,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $42.11 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health, Inc. has a one year low of $32.32 and a one year high of $63.20. The business’s 50-day simple moving average is $54.17 and its 200 day simple moving average is $47.80. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 32.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The business had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. During the same quarter in the previous year, the firm posted $0.47 earnings per share. As a group, sell-side analysts predict that Astrana Health, Inc. will post 1.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ASTH. Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. KeyCorp initiated coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Truist Financial boosted their price objective on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus boosted their price objective on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Finally, BTIG Research boosted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $65.17.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.